Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Polyclonal Antibody

Anti-Obinutuzumab Polyclonal Antibody

Catalog #:   PAC90701 Specific References (50) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: ELISA
Accession: CAS: 949142-50-1
Overview

Catalog No.

PAC90701

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

Obinutuzumab

Tested applications

ELISA: 1:4000-1:8000

Target

Rabbit polyclonal to Gazyva.

Specificity

The product is specific for Obinutuzumab. This antibody serves as an excellent positive control for Obinutuzumab immunogenicity (ADA) assays.

Concentration

0.21 mg/ml

Purification

Purified by antigen affinity column.

Accession

CAS: 949142-50-1

Applications

ELISA

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.

Background

Obinutuzumab is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It was approved under the trade name Gazyva by the US FDA in 2013, and as Gazyvaro by the EMA in Europe, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients, and as a second line treatment for follicular lymphoma. Obinutuzumab is a fully humanized monoclonal antibody that binds to an epitope on CD20 that partially overlaps with the epitope recognized by rituximab. Obinutuzumab binds to CD20 on B cells and causes these cells to be destroyed by engaging the adaptive immune system, directly activating intracellular apoptosis pathways, and activating the complement system.

Data Image
References

Advances and challenges in leukemia treatment: A focus on monoclonal antibodies and emerging therapies., PMID:40486885

Single-Agent and Associated Therapies with Monoclonal Antibodies: What About Follicular Lymphoma?, PMID:40427101

Obinutuzumab-Induced Inflammatory Bowel Disease-Like Colitis., PMID:40421460

Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy., PMID:40388905

Early caplacizumab and obinutuzumab enable successful treatment of relapsing thrombotic thrombocytopenic purpura without therapeutic plasma exchange: a case report., PMID:40356910

Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403., PMID:40355425

Clinical experience and safety of venetoclax in the treatment of patients with chronic lymphocytic leukemia - real-world data from a hemato-oncology center., PMID:40353625

Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy., PMID:40336511

[Seronegativity and anti-CD20: When a treatment compromises the diagnosis]., PMID:40312237

Obinutuzumab for treatment of membranous nephropathy in patients positive and negative for the phospholipase A2 receptor antibody: case reports., PMID:40303416

Obinutuzumab in Rituximab-Intolerant Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Patients., PMID:40303206

Osteonecrosis of the Jaw Associated with Obinutuzumab in a Patient with Preceding Follicular Non-Hodgkin's Lymphoma., PMID:40278317

How we manage immune-mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance., PMID:40270461

Clinical characteristics, treatment patterns and outcomes of patients with follicular lymphoma in Colombia: a real-world evidence cohort study., PMID:40227475

Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies., PMID:40225374

AMPLIFY: A second-generation BTK inhibitor for fixed-duration therapy in chronic lymphocytic leukemia., PMID:40220751

B cell depletion in lupus nephritis: From disappointments to hopes, despite some concerns., PMID:40220749

A New Pulmonary Nodule in a Patient With a History of Lymphoma., PMID:40210319

Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study., PMID:40181090

Treatment of nephrotic syndrome with anti-CD20 therapies in pregnancy: a case series and review of the literature., PMID:40148078

Preclinical B cell depletion and safety profile of a brain-shuttled crystallizable fragment-silenced CD20 antibody., PMID:40118783

The role of obinutuzumab in rituximab-refractory membranous nephropathy and minimal change disease., PMID:40104551

Anti-CD20 maintenance strategies to face the challenge of COVID-19 pandemic in follicular lymphoma: results from the R-FolSTOP multicentre Italian study., PMID:40074837

Bilateral drusenoid deposits with subretinal fluid and cystoid macular edema in a serum anti-phospholipase A2 receptor antibody positive patient: A case report., PMID:40061915

[The combined regimen based on obinutuzumab plus glucocorticoid for 4 cases of relapsed iTTP]., PMID:40059685

[Immune thrombotic thrombocytopenic purpura treated with Obinutuzumab: a case report and literature review]., PMID:40032339

Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma., PMID:40030008

Observation of the efficacy and safety of obinutuzumab in the treatment of refractory idiopathic membranous nephropathy., PMID:40025315

Obinutuzumab in membranous nephropathy: a potential game-changer in treatment., PMID:40017729

t(14;22)(q32;q11) translocation involving IGH and IGL acquired at progression of splenic marginal zone lymphoma treated with rituximab, ibrutinib, and obinutuzumab., PMID:40014084

Chemotherapy-free treatment with acalabrutinib can benefit patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who were never treated before: a plain language summary of the ELEVATE-TN study., PMID:40007474

Antibody Therapy for Patients with Lymphoid Malignancies: Past and Present., PMID:40004173

Obinutuzumab maintenance versus observation for patients with newly diagnosed high tumor burden follicular lymphoma who achieved complete metabolic response after obinutuzumab plus bendamustine induction therapy: a multicenter, randomized, phase III study (JCOG2008, MAIN study)., PMID:39997358

Obinutuzumab in Rituximab-resistant and recurrent membranous nephropathy: a case-series., PMID:39979558

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia., PMID:39976417

Low-dose obinutuzumab for steroid-dependent nephrotic syndrome complicated by recurrent rituximab-induced serum sickness and anti-rituximab antibodies., PMID:39966139

Efficacy and Safety of First-line Targeted Therapies in Physically Fit Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis., PMID:39952822

Two Are Better than One: The Bi-Specific Antibody Mosunetuzumab Reveals an Improved Immune Response of Vγ9Vδ2 T Cells Targeting CD20 in Malignant B Cells in Comparison to the Mono-Specific Antibody Obinutuzumab., PMID:39941030

Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis., PMID:39927615

MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial., PMID:39883943

Obinutuzumab in Difficult to Treat Phospholipase A2 Receptor Positive Membranous Nephropathy: Our Experience at a Tertiary Care Center in North India., PMID:39872260

Efficacy, safety and cost-effectiveness of obinutuzumab in patients with follicular lymphoma: a rapid review., PMID:39830356

Successful Switch to Obinutuzumab in a Rituximab-Intolerant Child with Difficult-to-Treat Idiopathic Nephrotic Syndrome., PMID:39797329

Decoding the molecular interplay of CD20 and therapeutic antibodies with fast volumetric nanoscopy., PMID:39787234

The real-world efficacy and safety of frontline therapy of obinutuzumab plus bendamustine for untreated high-tumor-burden follicular lymphoma., PMID:39776016

The treatment combination of obinutuzumab, bendamustine and dexamethasone achieved a deeper response than the previous line of treatment in five patients with Waldenström's macroglobulinemia., PMID:39772823

Obinutuzumab-induced acute thrombocytopenia: a case report and literature review., PMID:39741978

Acalabrutinib and Obinutuzumab for Chronic Lymphocytic Leukemia Complicated With Peripheral Neuropathy., PMID:39734995

SOHO State of the Art Updates and Next Questions | Venetoclax + Obinutuzumab Therapy in Chronic Lymphocytic Leukemia., PMID:39732538

In patients with follicular lymphoma, delayed-onset neutropenia induced by anti-CD20 monoclonal antibodies frequently occurs during maintenance therapy and is preferentially associated with obinutuzumab., PMID:39663256

Datasheet
$ 354
Product specifications
50 μg 354 100 μg 680

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Obinutuzumab Polyclonal Antibody [PAC90701]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only